Avalo Therapeutics, Inc. ( (AVTX) ) has released its Q3 earnings. Here is a breakdown of the information Avalo Therapeutics, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead asset, A VTX-009, in a Phase 2 clinical trial for hidradenitis suppurativa. The company recently released its earnings report for the quarter ending September 30, 2025, highlighting significant financial and operational metrics. Avalo reported a net loss of $30.6 million for the quarter, with no revenue generated, compared to a net income of $23 million in the same period last year. The company’s operating expenses increased to $19.2 million, driven by higher research and development costs. Despite the losses, Avalo maintains a strong cash position with $111.6 million in cash and short-term investments, ensuring operational funding for at least the next twelve months. Looking ahead, Avalo’s management remains focused on advancing its clinical programs and exploring strategic partnerships to support its long-term growth objectives.